Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea
Money ME, Walkowiak J, Virgilio C, Talley NJ
Published in Frontline Gastroenterology, Vol. 2 (1), pp. 48-56
Methodology
Randomized double-blind placebo-controlled crossover trial of a pancrelipase preparation before high-fat meals in patients with functional postprandial symptoms.
Key Findings
Pancrelipase reduced post-meal bloating, gas and cramping compared with placebo.
Conclusions
Enzyme supplementation can relieve fat-related digestive symptoms without diagnosed insufficiency.
Limitations
Small crossover study; single high-fat meal challenge.
Supplements Studied
Pancrelipase reduced post-meal bloating, gas and cramping compared with placebo
Outcomes Measured
Pancrelipase reduced post-meal bloating, gas and cramping compared with placebo
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.